Figure 4.
Figure 4. muLangerin-CD11c+ cells make stable interactions with CD8 cells. Irradiated 129 mice were reconstituted with B6 F1(muLangerin-DTRxCD11c-YFP) BM, RFP+ CD8 cells and unlabeled CD4 cells. Approximately 28 days after bone marrow transplantation, mice were treated with PBS or with DT. Mice were imaged 48 hours later. (A) Representative flow cytometry of digested skin, which demonstrates the depletion of CD103+MHCII+CD11c+ cells after DT treatment. (B) Still images from representative videos in PBS (left panel; supplemental Video 7) or DT (right panel; supplemental Video 8). The percentage of CD8 cells in continuous contact with YFP+ cells for at least 30’ or 40’ are shown in panel C. P = .26 comparing PBS and DT-treated groups. (D) Cumulative contact durations between CD8 cells and CD11c+ cells (of CD8 cells that ever contact the DC surface). P = .54.

muLangerin-CD11c+ cells make stable interactions with CD8 cells. Irradiated 129 mice were reconstituted with B6 F1(muLangerin-DTRxCD11c-YFP) BM, RFP+ CD8 cells and unlabeled CD4 cells. Approximately 28 days after bone marrow transplantation, mice were treated with PBS or with DT. Mice were imaged 48 hours later. (A) Representative flow cytometry of digested skin, which demonstrates the depletion of CD103+MHCII+CD11c+ cells after DT treatment. (B) Still images from representative videos in PBS (left panel; supplemental Video 7) or DT (right panel; supplemental Video 8). The percentage of CD8 cells in continuous contact with YFP+ cells for at least 30’ or 40’ are shown in panel C. P = .26 comparing PBS and DT-treated groups. (D) Cumulative contact durations between CD8 cells and CD11c+ cells (of CD8 cells that ever contact the DC surface). P = .54.

Close Modal

or Create an Account

Close Modal
Close Modal